Nitric oxide and the immunomodulation of experimental allergic encephalomyelitis.
Previous studies examining the effect of nitric oxide synthase (NOS) inhibition on the course of experimental allergic encephalomyelitis (EAE) have yielded conflicting results. This may relate to the use of nonspecific inhibitors and to differences between active and adoptive EAE. We examined the effect of treatment with L-N-(1-iminoethyl)lysine (L-NIL), a selective inhibitor of the cytokine-inducible isoform of NOS, on the clinical course of active and adoptive EAE in Lewis rats. We find that while L-NIL treatment of recipients is protective in adoptive EAE, treatment of active EAE with L-NIL leads to a marked accentuation of disease expression. In L-NIL-treated animals treated with myelin basic protein/complete Freund's adjuvant (MBP/CFA), disease onset is accelerated and clinical symptoms are more severe. Accentuation of integrated disease scores is seen even if L-NIL treatment is started 5 days following immunization. The histological findings in involved spinal cords from L-NIL-treated animals with active EAE are similar to those from untreated animals with similar clinical scores. L-NIL treatment of MBP/CFA-immunized animals does not prevent recovery from clinical symptoms, nor does it allow for reinduction of disease in animals previously immunized with MBP/CFA. Treatment of F344 rats, a strain which is relatively nonsusceptible for EAE, with L-NIL results in consistent evidence of EAE following immunization with MBP/CFA. These findings, together with our previous work on interstitial nephritis, support a role for endogenously generated NO in immunoregulation of T cell responses following immunization with antigen in CFA, and suggest that inducibility of NOS expression may be an important susceptibility factor for autoimmunity.
Gold
D P
DP
Sidney Kimmel Cancer Center, San Diego, CA 92121, USA. danpgold@aol.com
Schroder
K
K
Powell
H C
HC
Kelly
C J
CJ
D000276:Adjuvants, Immunologic / Q000096:biosynthesis / Q000502:physiology*; D000284:Administration, Oral; D019264:Adoptive Transfer; D000818:Animals; D003208:Concanavalin A / Q000494:pharmacology; D004198:Disease Susceptibility; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000201:enzymology / Q000209:etiology / Q000276:immunology* / Q000517:prevention & control; D005620:Freund's Adjuvant / Q000276:immunology; D007113:Immunity, Innate / Q000187:drug effects; D007371:Interferon-gamma / Q000096:biosynthesis / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D017710:Lymphocyte Transfusion; D008239:Lysine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004676:Myelin Basic Protein / Q000276:immunology; D009569:Nitric Oxide / Q000096:biosynthesis / Q000276:immunology* / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D051381:Rats; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D013045:Species Specificity; D013154:Spleen / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation
D000276:Adjuvants, Immunologic; D004676:Myelin Basic Protein; C090663:N(6)-(1-iminoethyl)lysine; D003208:Concanavalin A; D009569:Nitric Oxide; D007371:Interferon-gamma; D005620:Freund's Adjuvant; D019001:Nitric Oxide Synthase; D008239:Lysine